Experience

FutureGen Announces License Agreement With AbbVie

June 13, 2024

Cooley advised FutureGen Biopharmaceutical, an innovative biopharmaceutical company committed to providing high-quality innovative biologics for patients with cancer, immune diseases and other diseases, on its license agreement with AbbVie to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development.

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Xiaoyu Xu
Associate, Beijing
Aaron Pomeroy
Partner, Colorado
Geoffrey Spolyar
Partner, Boston
David Burns
Special Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Zhijing Yu
Associate, Singapore

Related Practices & Industries

ImmuneOnco Biopharmaceuticals – HK$319 Million IPO

September 5, 2023

Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million initial public offering.

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Xander Lee
Partner, Santa Monica
Francis Wheeler
Partner, Colorado
Eric Blanchard
Partner, Boston
Yiying Wang
Associate, Shanghai
Kaiting Yang
Associate, Hong Kong
Yunxiang Xu
Associate, Shanghai
Xiaoyu Xu
Associate, Beijing
Cecilia Bai
Associate , Singapore
Rick Jantz
Associate, Santa Monica
Cindy Pan
International Legal Project Manager, Hong Kong
Alex Wu
International Legal Project Manager, Shanghai
Zhengyang Li
International Legal Project Manager, Hong Kong

Related Practices & Industries

Laekna Announces Largest 18A IPO Year to Date at HK$791 Million

June 29, 2023

Cooley advised China International Capital Corporation Hong Kong Securities Limited (CICC) and other underwriters on Laekna’s HK$791 million (US$101 million) initial public offering of 63,728,000 shares on the Hong Kong Stock Exchange, the largest 18A offering year to date.

Read more

Related contacts

Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Tonny Yu
Associate, Hong Kong
Xiaoyu Xu
Associate, Beijing
April Wang
Associate, Hong Kong
Cindy Pan
International Legal Project Manager, Hong Kong
Blake Cao
Senior Legal Assistant, Beijing
Philip Kwan
Senior Legal Assistant, Hong Kong
Zhengyang Li
International Legal Project Manager, Hong Kong

Related Practices & Industries

IMPACT Therapeutics Announces Global License Collaboration Agreement With Eikon

June 14, 2023

Cooley advised IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality on its license and collaboration agreement with Eikon Therapeutics, a biotechnology company.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Xiaoyu Xu
Associate, Beijing
Xiaozhen (Shawn) Yu
Associate, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Chen Chen
Associate, Palo Alto

Related Practices & Industries

Zion Pharma Announces Sale of Lead Program to Roche

May 15, 2023

Cooley advised Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, on the acquisition of its lead program, ZN-A-1041, by Roche.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Aaron Pomeroy
Partner, Colorado
David Burns
Special Counsel, Washington, DC
Xiaoyu Xu
Associate, Beijing
Amanda Pacheco
Associate, Palo Alto
Chen Chen
Associate, Palo Alto

Related Practices & Industries

View more

Admissions and credentials

New York